GLAND Gland Pharma Q3 FY25 results (Oct–Dec 2024) and concall
Gland Pharma delivered a resilient Q3 FY25, characterized by significant margin expansion in its base business despite a revenue decline in that segment. While the consolidated performance was bolstered by new launches and improved product mix, the Cenexi acquisition continues to face operational and regulatory headwinds, delaying its EBITDA breakeven target. Management is pivoting towards high-value biologics and CDMO opportunities to drive long-term growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 1,063 | 1,011 |
| EBITDA | 364 | 391 |
| Net profit | 282 | 295 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
